Europe’s best-performing blue-chip inventory in 2025 is broadly anticipated to be purchased by a bigger peer, in a deal analysts say may very well be value as a lot as $23 billion.
Abivax, the French clinical-stage biotech firm growing a therapy for ulcerative colitis and Crohn’s illness, noticed shares rocket 1,681% final yr, far outpacing the Stoxx 600 index’s second-best performing inventory, mining firm Fresnillo, which rose 453%.
Now, the massive query for analysts appears to be when, not if, Abivax declares a deal.
The inventory, listed in 2015, largely ranged between 10 and 20 euros nevertheless it wasn’t till 10 years later that it actually took off. Shares surged 510% in a day after Abivax reported the outcomes of a late-stage trial for an ulcerative colitis drugs in July, beating even essentially the most optimistic expectations. After these sorts of outcomes, it may very well be a strategic acquisition for any massive pharmaceutical firm with an immunology and irritation franchise.
Abivax‘s lead – and solely – asset, obefazimod, was first developed as a therapy for HIV, however researchers found that its anti-inflammatory impact may have an effect on different situations like inflammatory bowel illness (IBD) and started scientific trials.
Shares have been boosted much more in December as rumors emerged that the world’s most respected pharma firm, Eli Lilly, had its eyes set on buying Abivax. Each corporations have repeatedly declined to touch upon enterprise growth actions.
An imminent deal?
Analysts say {that a} deal may occur any time now.
Van Lanschot Kempen analyst Sebastiaan van der Schoot informed CNBC that biotechs typically “have a comparatively small variety of staff and haven’t any expertise with promoting a drug,” which he referred to as “a totally completely different ball recreation” to growing them.
“That is why pharma takes them out to really leverage their infrastructure,” he stated.
The analyst added that he anticipated Abivax to commerce between the place it’s now and the place it was when rumors of a takeover first surfaced, till the annual JP Morgan Healthcare Convention on Monday, the place corporations typically announce massive offers.
Abivax shares surged in 2025, far outpacing European friends.
It comes as Massive Pharma has ramped up dealmaking in latest months, because the sector faces a looming patent cliff the place a few of the world’s best-selling medicine lose exclusivity within the coming years.
One other issue making a deal likelier is Abivax CEO Marc de Garidel‘s status as a pacesetter who could make offers occur. He beforehand led multi-billion greenback buyouts of biotech corporations to pharma gamers like AstraZeneca and Novo Nordisk.
Requested a couple of potential acquisition, de Garidel informed CNBC’s “Europe Early Version” in December that the corporate was all the time in “dialog with Massive Pharma” however that its function was to develop the absolute best drug.
Abivax is planning to file for regulatory approval within the U.S. by the tip of 2026, eyeing a possible launch by the third quarter of 2027, de Garidel stated.
The corporate is well-positioned to barter a good take care of a Massive Pharma companion, Stifel analyst Damien Choplain stated.
“Given the power of the Section III outcomes and the shortage of comparable property, we consider a transaction may very well be executed forward of the upkeep knowledge readout anticipated in Q2 2026,” he stated, referring to a second scientific trial of Obefazimod which assessments its efficacy over 44 weeks versus solely eight weeks.
Choplain added that almost all transactions within the IBD house have traditionally occurred for drug candidates in earlier phases of growth. “Abivax ticks all of the bins for a strategic acquisition,” he stated.
Based mostly on comparable transactions and a peak gross sales estimate of three billion euros, Abivax’s valuation may vary between 12 billion euros and 20 billion euros ($14 billion to $23 billion), Choplain informed CNBC.
Current offers within the IBD house embody Merck’s acquisition of Prometheus for $10.8 billion; Roche’s acquisition of Telavant for $7.1 billion; and Eli Lilly shopping for Morphic for $3.2 billion. These offers have been all for property in an earlier stage of growth than Abivax’s obefazimod.
A possible best-in-class therapy
Jefferies analyst Roger Track, who would not cowl Abivax per se however tracks the IBD house intently from Boston, stated that traders’ optimism comes each from a multi-billion greenback potential marketplace for IBD remedies, in addition to from the drug candidate’s novel method of addressing it by means of a number of pathways.
It’s even thought-about to be a possible best-in-class therapy for ulcerative colitis, he informed CNBC in December.
The July outcomes from the trial of Obefazimod stunned traders as a result of many had not been conscious of the novel mechanism it makes use of, micro-RNA, Track stated.
A late-stage upkeep trial is predicted within the second quarter of 2026.
Van der Schoot added that, if Abivax is assured sufficient in these upkeep outcomes, it could possibly wait to be acquired after the trial is revealed, “as a result of then they will ask the next value.”
